Highlight
Among 954 pregnancies complicated by type 2 diabetes, 34.3% had gestational weight gain under 5 kg.
Weight gain under 5 kg was associated with lower adjusted odds of large-for-gestational-age birth weight, neonatal intensive care unit admission, hypertensive disorders of pregnancy, and cesarean delivery.
The study did not detect a statistically significant increase in small-for-gestational-age birth weight or preterm birth with weight gain under 5 kg, although the confidence interval for small-for-gestational-age crossed 1 and leaves residual uncertainty.
These findings support re-examining gestational weight targets in pregnant individuals with type 2 diabetes, while emphasizing the need for prospective interventional trials before practice recommendations are changed.
Background
Pregnancy complicated by type 2 diabetes is increasingly common and remains high risk. Compared with pregnancies without diabetes, these pregnancies carry elevated risks of congenital anomalies, hypertensive disorders of pregnancy, cesarean delivery, fetal overgrowth, shoulder dystocia, neonatal hypoglycemia, and neonatal intensive care unit admission. Many of these adverse outcomes are driven not only by hyperglycemia but also by coexisting obesity, insulin resistance, and metabolic inflammation.
Gestational weight gain is a clinically modifiable factor that intersects with all of these mechanisms. Current weight gain counseling in pregnancy is usually anchored to prepregnancy body mass index categories and Institute of Medicine/National Academy of Medicine guidance, but such recommendations were not specifically designed for patients with type 2 diabetes. In routine practice, clinicians often face a difficult balance: too much weight gain may worsen insulin resistance and fetal overgrowth, yet overly restrictive gain raises concern for fetal growth restriction or preterm birth. Evidence specific to type 2 diabetes has been limited, particularly in large contemporary cohorts managed with modern diabetes therapies.
The study by Crites and colleagues addresses this important evidence gap by examining whether restricted gestational weight gain or even weight loss, defined pragmatically as total gain under 5 kg, is associated with better or worse perinatal outcomes in pregnancies affected by type 2 diabetes.
Study Design
Design and setting
This was a retrospective cohort study conducted across two academic health centers.
Population
The investigators included 954 pregnant individuals with type 2 diabetes. The abstract does not provide full inclusion and exclusion details, but the cohort appears designed to reflect real-world obstetric care in tertiary academic practice.
Exposure of interest
The primary exposure was total gestational weight gain under 5 kg, which included both restricted gain and net weight loss. This group was compared with pregnancies with weight gain of 5 kg or more. Of the 954 pregnancies, 327, or 34.3%, were in the under-5-kg group.
Variables assessed
The investigators compared maternal demographics, health care utilization, glycemia, and diabetes therapies between groups. This is important because gestational weight gain may reflect baseline metabolic status, disease severity, treatment intensity, and access to prenatal care.
Outcomes
The reported perinatal outcomes included large-for-gestational-age birth weight, small-for-gestational-age birth weight, neonatal intensive care unit admission, hypertensive disorders of pregnancy, cesarean delivery, and preterm birth.
Statistical approach
Logistic regression analyses were used to compare outcomes between exposure groups, adjusted for covariates. The abstract does not list the full adjustment set, so readers should be cautious about residual confounding. Nevertheless, adjusted odds ratios provide a more clinically useful estimate than unadjusted event rates alone in an observational analysis.
Key Findings
Large-for-gestational-age birth weight
The most striking association was with fetal overgrowth. Weight gain under 5 kg was linked to substantially lower odds of large-for-gestational-age birth weight, with an adjusted odds ratio of 0.42 and a 95% confidence interval of 0.29 to 0.59. This corresponds to an estimated 58% relative reduction in the odds of delivering an infant with birth weight above the gestational-age threshold.
Clinically, this is highly relevant. Large-for-gestational-age birth weight is a central pathway through which diabetes in pregnancy contributes to labor complications, shoulder dystocia, operative delivery, postpartum hemorrhage, and neonatal metabolic instability. If the association is causal, limiting excess gestational weight gain could represent a meaningful adjunct to glycemic management.
Hypertensive disorders of pregnancy
Weight gain under 5 kg was also associated with lower odds of hypertensive disorders of pregnancy, with an adjusted odds ratio of 0.56 and a 95% confidence interval of 0.42 to 0.75. This suggests a 44% relative reduction in the adjusted odds of hypertensive disease.
This finding is biologically plausible. Greater gestational weight gain may amplify insulin resistance, systemic inflammation, endothelial dysfunction, and volume-related hemodynamic stress, all of which may contribute to hypertensive complications. In a population already at increased cardiovascular and obstetric risk, even a moderate reduction in this outcome could be clinically important.
Cesarean delivery
Cesarean delivery was less frequent in the under-5-kg group, with an adjusted odds ratio of 0.66 and a 95% confidence interval of 0.48 to 0.91. The pathway here is likely multifactorial. Lower rates of large-for-gestational-age infants and hypertensive disorders probably contributed, but there may also be institutional or clinician-level factors not fully captured by the analysis.
From a health systems perspective, any reduction in cesarean delivery has downstream implications for maternal recovery, future pregnancy risk, and resource utilization.
Neonatal intensive care unit admission
Neonatal intensive care unit admission was also lower among pregnancies with weight gain under 5 kg, with an adjusted odds ratio of 0.74 and a 95% confidence interval of 0.55 to 0.98. The effect size is smaller than for fetal overgrowth or hypertensive disease but still potentially meaningful.
NICU admission is a broad endpoint and may reflect diverse mechanisms, including respiratory morbidity, prematurity, metabolic instability, birth trauma, or institutional practices. The abstract does not specify the dominant drivers of the reduction, which limits mechanistic interpretation.
Small-for-gestational-age birth weight
A critical safety concern with restricted weight gain is undernutrition and fetal growth restriction. In this study, the adjusted odds ratio for small-for-gestational-age birth weight was 1.61, with a 95% confidence interval of 0.96 to 2.71. Because the confidence interval includes 1, the result was not statistically significant by conventional thresholds.
However, the point estimate trends upward, and the upper bound is compatible with a clinically meaningful increase. This is an important nuance. The absence of statistical significance is not equivalent to proof of safety. The data are somewhat reassuring but do not fully exclude harm in a subset of pregnancies, especially if fetal growth is already vulnerable because of placental disease, nephropathy, smoking, or intensive caloric restriction.
Preterm birth
There was no apparent increase in preterm birth, with an adjusted odds ratio of 0.92 and a 95% confidence interval of 0.67 to 1.25. This suggests no meaningful association in either direction based on the available data.
Because preterm birth can be spontaneous or medically indicated, and because hypertensive disorders often trigger indicated preterm delivery, the neutral overall finding likely reflects a balance of multiple competing effects.
Clinical Interpretation
This study adds to a growing body of literature suggesting that conventional gestational weight gain targets may be too high for some pregnancies complicated by obesity and type 2 diabetes. The observed reduction in large-for-gestational-age birth weight is especially compelling because fetal overgrowth remains one of the most persistent clinical problems in diabetes pregnancy, even when glycated hemoglobin appears acceptable.
The findings also fit current understanding of maternal-fetal metabolism. Excess maternal adiposity and weight gain can worsen hepatic and peripheral insulin resistance, increase circulating glucose, triglycerides, and free fatty acids, and enhance placental nutrient transfer. These changes may promote fetal hyperinsulinemia and somatic growth independent of measured glucose alone. Restricting excessive weight gain may therefore improve outcomes through pathways that are glycemic and nonglycemic.
At the same time, clinicians should not overinterpret the data as support for universal weight-loss goals during pregnancy. The exposure group included both low gain and net weight loss, and the abstract does not tell us whether risk differed across these patterns. Nor does it clarify how outcomes varied by prepregnancy body mass index, insulin use, baseline glycemic control, or gestational age at delivery. A patient with severe obesity and marked insulin resistance may not carry the same risk-benefit profile as a leaner patient with longstanding vascular disease.
Strengths and Limitations
Strengths
The cohort was relatively large for this specific clinical population and came from two academic centers, which may improve internal consistency and contemporary relevance. The exposure definition is simple and clinically recognizable. The use of adjusted regression analysis strengthens the inference compared with unadjusted comparisons.
Limitations
As a retrospective observational study, the analysis cannot establish causality. Patients who gain less weight may differ systematically from those who gain more in ways that are incompletely measured, including diet quality, social determinants of health, diabetes duration, baseline body mass index, medication adherence, severity of obesity, and clinician management style. Reverse causation is also possible in some settings; for example, patients with closer specialist follow-up may achieve both lower weight gain and better glycemic control.
The abstract does not report absolute event rates for each endpoint, the full covariate list, subgroup analyses, or how gestational weight gain was measured and standardized across centers. Without these details, it is difficult to judge the robustness of the effect estimates. The broad under-5-kg category also combines heterogeneous trajectories, from slight gain to actual weight loss.
The small-for-gestational-age result deserves particular caution. Although not statistically significant, the confidence interval is wide enough to leave open the possibility of increased risk. Future work should distinguish constitutionally small infants from pathologic fetal growth restriction and should incorporate serial ultrasound growth assessments.
How This Fits With Existing Guidance and Literature
Current U.S. guidance on gestational weight gain is based largely on prepregnancy body mass index and is not tailored specifically to pregestational type 2 diabetes. The 2009 Institute of Medicine recommendations remain influential, but clinicians have long recognized that they may not optimally address the metabolic profile of patients with diabetes and obesity.
Professional guidance from the American Diabetes Association emphasizes preconception counseling, tight glucose management, and multidisciplinary care in diabetes pregnancy, while also acknowledging that obesity and excessive gestational weight gain contribute to adverse maternal and neonatal outcomes. The present study strengthens the argument that glycemic metrics alone do not fully capture modifiable risk.
Prior studies in broader obstetric populations, especially among individuals with obesity, have suggested that lower-than-recommended gestational weight gain may reduce large-for-gestational-age birth, cesarean delivery, and hypertensive complications, though sometimes at the expense of higher small-for-gestational-age rates. What is new here is the focus on type 2 diabetes, a group in whom fetal overgrowth and maternal metabolic burden are especially pronounced.
Implications for Practice
For now, this study should prompt thoughtful counseling rather than abrupt changes in guidelines. In pregnant individuals with type 2 diabetes, clinicians may reasonably place greater emphasis on avoiding excessive gestational weight gain while maintaining nutritional adequacy and close fetal surveillance. Practical strategies include individualized medical nutrition therapy, structured physical activity when appropriate, optimization of diabetes medications, and frequent review of weight trajectory alongside glucose data.
Importantly, any attempt to limit gestational weight gain should be framed around metabolic health rather than caloric restriction alone. Adequate protein, micronutrient intake, and monitoring of fetal growth remain essential. Patients with nausea, food insecurity, renal disease, eating disorder history, or evidence of placental insufficiency may require especially cautious management.
Research Priorities
The authors appropriately call for interventional studies. The next step should not simply be to compare lower versus higher weight gain targets, but to test specific strategies capable of safely achieving healthier trajectories. These may include intensive nutrition counseling, continuous glucose monitoring-guided management, anti-obesity-informed behavioral interventions adapted for pregnancy, and carefully selected pharmacologic approaches where safety is established.
Future studies should also stratify by prepregnancy body mass index, race and ethnicity, treatment regimen, diabetes duration, kidney disease, and baseline glycemic control. Prospective designs with ultrasound-based fetal growth monitoring and longer-term offspring follow-up would be particularly valuable, since excess fetal growth may influence later cardiometabolic health.
Conclusion
In this retrospective cohort of 954 pregnancies complicated by type 2 diabetes, gestational weight gain under 5 kg was associated with significantly lower adjusted odds of large-for-gestational-age birth weight, hypertensive disorders of pregnancy, neonatal intensive care unit admission, and cesarean delivery. The study did not find a statistically significant increase in preterm birth or small-for-gestational-age birth weight, though uncertainty remains for the latter outcome.
The findings are clinically provocative and biologically plausible. They suggest that in type 2 diabetes pregnancy, limiting excess gestational weight gain may be an important adjunct to glucose management. But because the evidence comes from an observational study, it should be used to inform individualized counseling and future trial design, not yet to mandate new universal weight gain targets.
Funding and ClinicalTrials.gov
The abstract provided does not report funding details or a ClinicalTrials.gov registration number. As this was a retrospective cohort study, trial registration may not have been applicable.
References
1. Crites K, Pape K, Sherman K, Mai M, Kabele C, Altavilla A, Cleary EM, Scifres CM. Perinatal Outcomes in Pregnancies With Type 2 Diabetes and Weight Gain Less Than 5 Kilograms. Diabetes Care. 2026 May 28. PMID: 42207920.
2. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes. Diabetes Care. 2025;48(Suppl 1). This Standards chapter addresses glycemic targets, preconception counseling, and management principles relevant to pregnancies affected by diabetes.
3. Institute of Medicine and National Research Council. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington, DC: National Academies Press; 2009.
